Controversies in Targeted Therapy of Adult T Cell Leukemia/Lymphoma: ON Target or OFF Target Effects?
Abstract
:1. The First Potential Target: HTLV-I Retrovirus
2. The Second Potential Target: The Viral Oncoprotein Tax
3. Is Tax Really a Target in ATL?
4. Conventional Therapy for ATL
5. Targeted Therapies for ATL
5.1. Breakthrough in ATL Therapy: The Combination of Zidovudine and Interferon-Alpha
5.2. The AZT/IFN Combination: Is it an Antiviral Therapy?
5.3. Targeting ATL Leukemia Initiating Activity: The Combination of Arsenic Trioxide and IFN
5.4. Are We Really Targeting Tax?
6. Conclusion
Acknowledgments
References and Notes
- Matsuoka, M. Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene 2003, 22, 5131–5140. [Google Scholar] [CrossRef]
- Kaplan, J.E.; Khabbaz, R.F. The epidemiology of human T-lymphotropic virus types I and II. Rev. Med. Virol. 1993, 3, 137–148. [Google Scholar] [CrossRef]
- Nagai, M.; Osame, M. Human T-cell lymphotropic virus type I and neurological diseases. J. Neurovirol. 2003, 9, 228–235. [Google Scholar] [CrossRef]
- Abbaszadegan, M.R.; Gholamin, M.; Tabatabaee, A.; Farid, R.; Houshmand, M.; Abbaszadegan, M. Prevalence of human T-lymphotropic virus type 1 among blood donors from Mashhad, Iran. J. Clin. Microbiol. 2003, 41, 2593–2595. [Google Scholar] [CrossRef]
- Hinuma, Y.; Komoda, H.; Chosa, T.; Kondo, T.; Kohalura, M.; Takenaka, T.; Kikichu, M.; Ichimaru, M.; Yunoki, K.; Sato, I.; Matsuo, R.; Takiuchi, Y.; Uchino, H.; Hanaoka, M. Antibodies to adult T-cell leukemia-virus-associated antigen (ATLA) in sera from patients with ATL and controls in Japan: A nation-wide sero-epidemiologic study. Int. J. Cancer 1982, 29, 631–635. [Google Scholar] [CrossRef]
- Gessain, A.; Barin, F.; Vernant, J.C.; Gout, O.; Maurs, L.; Calender, A.; De The, G. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985, 2, 407–410. [Google Scholar] [CrossRef]
- Osame, M.; Usuku, K.; Izumo, S.; Ijichi, N.; Amitani, H.; Igata, A.; Matsumoto, M.; Tara, M. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986, 1, 1031–1032. [Google Scholar] [CrossRef]
- Carvalho, E.M.; Da Fonseca Porto, A. Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis. Parasite Immunol. 2004, 26, 487–497. [Google Scholar] [CrossRef]
- Giam, C.Z.; Jeang, K.T. HTLV-1 Tax and adult T-cell leukemia. Front. Biosci. 2007, 12, 1496–1507. [Google Scholar] [CrossRef]
- Okamoto, T.; Ohno, Y.; Sugane, S.; Watanabe, S.; Shimoyama, M.; Tajima, K.; Miwa, M.; Shimotohno, K. Multi-step carcinogenesis model for adult T-cell leukemia. Jpn. J. Canc. Res. 1989, 80, 191–195. [Google Scholar] [CrossRef]
- Yoshida, M.; Seiki, M.; Yamaguchi, K.; Takatsuki, K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc. Natl. Acad. Sci. U. S. A. 1984, 81, 2534–2537. [Google Scholar] [CrossRef]
- Hisada, M.; Okayama, A.; Shioiri, S.; Spiegelman, D.L.; Stuver, S.O.; Mueller, N.E. Risk factors for adult T-cell leukemia among carriers of human T-lymphotropic virus type I. Blood 1998, 92, 3557–3561. [Google Scholar] [CrossRef]
- Okayama, A.; Tachibana, N.; Ishihara, S.; Nagatomo, Y.; Murai, K.; Okamoto, M.; Shima, T.; Sagawa, K.; Tsubouchi, H.; Stuver, S.; et al. Increased expression of interleukin-2 receptor alpha on peripheral blood mononuclear cells in HTLV-I tax/rex mRNA-positive asymptomatic carriers. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1997, 15, 70–75. [Google Scholar] [CrossRef]
- Slamon, D.J.; Shimotohno, K.; Cline, M.J.; Golde, D.W.; Chen, I.S. Identification of the putative transforming protein of the human T-cell leukemia viruses HTLV-I and HTLV-II. Science 1984, 226, 61–65. [Google Scholar] [CrossRef]
- Gaudray, G.; Gachon, F.; Basbous, J.; Biard-Piechaczyk, M.; Devaux, C.; Mesnard, J. The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J. Virol. 2002, 76, 12813–12822. [Google Scholar] [CrossRef]
- Kannian, P.; Green, P.L. Human T Lymphotropic Virus Type 1 (HTLV-1): Molecular Biology and Oncogenesis. Viruses 2010, 2, 2037–2077. [Google Scholar] [CrossRef]
- Journo, C.; Douceron, E.; Mahieux, R. HTLV gene regulation: because size matters, transcription is not enough. Future Microbiol. 2009, 4, 425–440. [Google Scholar] [CrossRef]
- Manel, N.; Kim, F.J.; Kinet, S.; Taylor, N.; Sitbon, M.; Battini, J.L. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 2003, 115, 449–459. [Google Scholar] [CrossRef]
- Ghez, D.; Lepelletier, Y.; Jones, K.S.; Pique, C.; Hermine, O. Current concepts regarding the HTLV-1 receptor complex. Retrovirology 2010, 7, 99. [Google Scholar] [CrossRef]
- Ghez, D.; Lepelletier, Y.; Lambert, S.; Fourneau, J.M.; Blot, V.; Janvier, S.; Arnulf, B.; van Endert, P.M.; Heveker, N.; Pique, C.; Hermine, O. Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry. J. Virol. 2006, 80, 6844–6854. [Google Scholar] [CrossRef]
- Takenouchi, N.; Jones, K.S.; Lisinski, I.; Fugo, K.; Yao, K.; Cushman, S.W.; Ruscetti, F.W.; Jacobson, S. GLUT1 is not the primary binding receptor but is associated with cell-to-cell transmission of human T-cell leukemia virus type 1. J. Virol. 2007, 81, 1506–1510. [Google Scholar] [CrossRef]
- Lambert, S.; Bouttier, M.; Vassy, R.; Seigneuret, M.; Petrow-Sadowski, C.; Janvier, S.; Heveker, N.; Ruscetti, F.W.; Perret, G.; Jones, K.S.; Pique, C. HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165. Blood 2009, 113, 5176–5185. [Google Scholar] [CrossRef]
- Sibon, D.; Gabet, A.S.; Zandecki, M.; Pinatel, C.; Thête, J.; Delfau-Larue, M.H.; Rabaaoui, S.; Gessain, A.; Gout, O.; Jacobson, S.; Mortreux, F.; Wattel, E. HTLV-1 propels untransformed CD4 lymphocytes into the cell cycle while protecting CD8 cells from death. J. Clin. Invest. 2006, 116, 974–983. [Google Scholar] [CrossRef]
- Zane, L.; Sibon, D.; Jeannin, L.; Zandecki, M.; Delfau-Larue, M.H.; Gessain, A.; Gout, O.; Pinatel, C.; Lançon, A.; Mortreux, F.; Wattel, E. Tax gene expression and cell cycling but not cell death are selected during HTLV-1 infection in vivo. Retrovirology 2010, 11, 7–17. [Google Scholar] [CrossRef] [PubMed]
- Franchini, G. Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood 1995, 86, 3619–3639. [Google Scholar] [CrossRef] [PubMed]
- Gatza, M.L.; Watt., J.C.; Marriott, S.J. Cellular Transformation by the HTLV-I Tax Protein, a Jack-of-All-Trades. Oncogene 2003, 22, 5141–5149. [Google Scholar] [CrossRef] [PubMed]
- Kfoury, Y.; Nasr, R.; Hermine, O.; de Thé, H.; Bazarbachi, A. Proapoptotic regimes for HTLV-I-transformed cells: Targeting Tax and the NF-kappaB pathway. Cell Death Differ. 2005, 12, 871–877. [Google Scholar] [CrossRef]
- Sun, S.C.; Elwood, J.; Béraud, C.; Greene, W.C. Human T-cell leukemia virus type I Tax activation of NF-kappa B/Rel involves phosphorylation and degradation of I kappa B alpha and RelA (p65)-mediated induction of the c-rel gene. Mol. Cell Biol. 1994, 14, 7377–7384. [Google Scholar] [CrossRef]
- Good, L.; Sun, S.C. Persistent activation of NF-kappa B/Rel by human T-cell leukemia virus type 1 tax involves degradation of I kappa B beta. J. Virol. 1996, 70, 2730–2735. [Google Scholar] [CrossRef]
- Yin, M.J.; Christerson, L.B.; Yamamoto, Y.; Kwak, Y.T.; Xu, S.; Mercurio, F.; Barbosa, M.; Cobb, M.H.; Gaynor, R.B. HTLV-I Tax protein binds to MEKK1 to stimulate IkappaB kinase activity and NF-kappaB activation. Cell 1998, 93, 875–884. [Google Scholar] [CrossRef]
- Uhlik, M.; Good, L.; Xiao, G.; Harhaj, E.W.; Zandi, E.; Karin, M.; Sun, S.C. NF-kappaB-inducing kinase and IkappaB kinase participate in human T-cell leukemia virus I Tax-mediated NF-kappaB activation. J. Biol. Chem. 1998, 273, 21132–21136. [Google Scholar] [CrossRef]
- Journo, C.; Filipe, J.; About, F.; Chevalier, S.A.; Brady, J.N.; Afonso, P.V.; Flynn, D.; Tangy, F.; Israël, A.; Vidalain, P.O.; Weil, R.; Mahieux, R. NRP/Optineurin Cooperates with TAX1BP1 to Potentiate the Activation of NF-κB by Human T-Lymphotropic Virus Type 1 Tax Protein. PLoS Pathog. 2009, 5, e1000521. [Google Scholar] [CrossRef] [PubMed]
- Xiao, G.; Cvijic, M.E.; Fong, A.; Harhaj, E.W.; Uhlik, M.T.; Waterfield, M.; Sun, S.C. Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha. EMBO J. 2001, 20, 6805–6815. [Google Scholar] [CrossRef]
- Zhao, L.J.; Giam, C.Z. Human T-cell lymphotropic virus type I (HTLV-I) transcriptional activator, Tax, enhances CREB binding to HTLV-I 21 base-pair repeats by protein-protein interaction. Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 7070–7074. [Google Scholar] [CrossRef] [PubMed]
- Suzuki, T.; Fujisawa, J.I.; Toita, M.; Yoshida, M. The trans-activator tax of human T-cell leukemia virus type 1 (HTLV-1) interacts with cAMP-responsive element (CRE) binding and CRE modulator proteins that bind to the 21-base-pair enhancer of HTLV-1. Proc. Natl. Acad. Sci. U. S. A. 1993, 90, 610–614. [Google Scholar] [CrossRef]
- Fujii, M.; Tsuchiya, H.; Chuhjo, T.; Akizawa, T. ; Seiki, M: Interaction of HTLV-I Taxl with p67SRF causes the aberrant induction of cellular immediate early genes through CArG boxes. Gene. Dev. 1992, 6, 2066–2076. [Google Scholar] [CrossRef]
- Fujii, M.; Iwai, K.; OIie, M.; Fukushi, M.; Yamamoto, N.; Kannagi, M.; Mori, N. Activation of oncogenic transcription factor AP-1 in T cells infected with the human T-cell leukemia virus type 1. AIDS Res. Hum. Retrovir. 2000, 16, 1603–1606. [Google Scholar] [CrossRef]
- Kfoury, Y.; Setterblad, N.; El-Sabban, M.; Zamborlini, A.; Dassouki, Z.; El Hajj, H.; Hermine, O.; Pique, C.; de Thé, H.; Saïb, A.; Bazarbachi, A. Tax ubiquitylation and SUMOylation control the dynamic shuttling of Tax and NEMO between Ubc9 nuclear bodies and the centrosome. Blood 2011, 117, 190–199. [Google Scholar] [CrossRef] [PubMed]
- Kfoury, Y.; Nasr, R.; Favre-Bonvin, A.; El-Sabban, M.; Renault, N.; Giron, M.L.; Setterblad, N.; Hajj, H.E.; Chiari, E.; Mikati, A.G.; Hermine, O.; Saib, A.; de Thé, H.; Pique, C.; Bazarbachi, A. Ubiquitylated Tax targets and binds the IKK signalosome at the centrosome. Oncogene 2008, 27, 1665–1676. [Google Scholar] [CrossRef] [PubMed]
- Nasr, R.; Chiari, E.; El-Sabban, M.; Mahieux, R.; Kfoury, Y.; Abdulhay, M.; Yazbeck, V.; Hermine, O.; de Thé, H.; Pique, C.; Bazarbachi, A. Tax ubiquitylation and sumoylation control critical cytoplasmic and nuclear steps of NF-kappaB activation. Blood 2006, 107, 4021–4029. [Google Scholar] [CrossRef]
- Jeang, K.T.; Widen, S.G.; Semmes, O.J., 4th; Wilson, S.H. HTLV-I trans-activator protein, tax, is a trans-repressor of the human beta-polymerase gene. Science 1990, 247, 1082–1084. [Google Scholar] [CrossRef] [PubMed]
- Kibler, K.V.; Jeang, K.T. CREB/ATF-dependent repression of cyclin a by human T-cell leukemia virus type 1 Tax protein. J. Virol. 2001, 75, 2161–2173. [Google Scholar] [CrossRef]
- Arnulf, B.; Villemain, A.; Nicot, C.; Mordelet, E.; Charneau, P.; Kersual, J.; Zermati, Y.; Mauviel, A.; Bazarbachi, A.; Hermine, O. Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta 1 signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-I leukemogenesis. Blood 2002, 100, 4129–4138. [Google Scholar] [CrossRef]
- Nicot, C.; Mahieux, R.; Takemoto, S.; Franchini, G. Bcl-X(L) is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. Blood 2000, 96, 275–281. [Google Scholar] [CrossRef]
- Pise-Masison, C.A.; Choi, K.S.; Radonovich, M.; Dittmer, J.; Kim, S.J.; Brady, J.N. Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein. J. Virol. 1998, 72, 1165–1170. [Google Scholar] [CrossRef] [PubMed]
- Suzuki, T.; Yoshida, M. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16Ink4a and counteracts its inhibitory activity to CDK4. Leukemia 1997, 11, 14–16. [Google Scholar] [CrossRef]
- Afonso, P.V.; Zamborlini, A.; Saab, A.; Mahieux, R. Centrosome and retroviruses: the dangerous liaisons. Retrovirology 2007, 14, 4–27. [Google Scholar] [CrossRef]
- Jeang, K.T. Human T cell leukemia virus type 1 (HTLV-1) and oncogene or oncomiR addiction? Oncotarget 2010, 1, 453–456. [Google Scholar] [CrossRef]
- Matsumoto, K.; Shibata, H.; Fujisawa, J.I.; Inoue, H.; Hakura, A.; Tsukahara, T.; Fujii, M. Human T-cell leukemia virus type 1 Tax protein transforms rat fibroblasts via two distinct pathways. J. Virol. 1997, 71, 4445–4451. [Google Scholar] [CrossRef] [PubMed]
- Grassmann, R.; Berchtold, S.; Radant, I.; Alt, M.; Fleckenstein, B.; Sodroski, J.G.; Haseltine, W.A.; Ramstedt, U. Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in culture. J. Virol. 1992, 66, 4570–4575. [Google Scholar] [CrossRef]
- Hasegawa, H.; Sawa, H.; Lewis, M.J.; Orba, Y.; Sheehy, N.; Yamamoto, Y.; Ichinohe, T.; Tsunetsugu-Yokota, Y.; Katano, H.; Takahashi, H.; Matsuda, J.; Sata, T.; Kurata, T.; Nagashima, K.; Hall, W.W. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat. Med. 2006, 12, 466–472. [Google Scholar] [CrossRef] [PubMed]
- Banerjee, P.; Tripp, A.; Lairmore, M.D.; Crawford, L.; Sieburg, M.; Ramos, J.C.; Harrington, W., Jr.; Beilke, M.A.; Feuer, G. Adult T-cell leukemia/lymphoma development in HTLV-1-infected humanized SCID mice. Blood 2010, 115, 2640–2648. [Google Scholar] [CrossRef] [PubMed]
- Tamiya, S.; Matsuoka, M.; Etoh, K.; Watanabe, T.; Kamihira, S.; Yamaguchi, K.; Takatsuki, K. Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood 1996, 88, 3065–3073. [Google Scholar] [CrossRef] [PubMed]
- Furukawa, Y.; Kubota, R.; Tara, M.; Izumo, S.; Osame, M. Existence of escape mutant in HTLV-I tax during the development of adult T-cell leukemia. Blood 2001, 97, 987–993. [Google Scholar] [CrossRef]
- Koiwa, T.; Hamano-Usami, A.; Ishida, T.; Okayama, A.; Yamaguchi, K.; Kamihira, S.; Watanabe, T. 5’-long terminal repeat-selective CpG methylation of latent human T-cell leukemia virus type 1 provirus in vitro and in vivo. J. Virol. 2002, 76, 9389–9397. [Google Scholar] [CrossRef]
- Takeda, S.; Maeda, M.; Morikawa, S.; Taniguchi, Y.; Yasunaga, J.; Nosaka, K.; Tanaka, Y.; Matsuoka, M. Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int. J. Cancer. 2004, 109, 559–567. [Google Scholar] [CrossRef]
- Basbous, J.; Arpin, C.; Gaudray, G.; Piechaczyk, M.; Devaux, C.; Mesnard, J.M. The HBZ factor of human T-cell leukemia virus type I dimerizes with transcription factors JunB and c-Jun and modulates their transcriptional activity. J. Biol. Chem. 2003, 278, 43620–43627. [Google Scholar] [CrossRef]
- Taylor, J.M.; Ghorbel, S.; Nicot, C. Genome wide analysis of human genes transcriptionally and post-transcriptionally regulated by the HTLV-I protein p30. BMC Genomics 2009, 10, 311. [Google Scholar] [CrossRef]
- Datta, A.; Silverman, L.; Phipps, A.J.; Hiraragi, H.; Ratner, L.; Lairmore, M.D. Human T-lymphotropic virus type-1 p30 alters cell cycle G2 regulation of T lymphocytes to enhance cell survival. Retrovirology 2007, 4, 49. [Google Scholar] [CrossRef]
- Liu, M.; Yang, L.; Zhang, L.; Liu, B.; Merling, R.; Xia, Z.; Giam, C.Z. Human T-cell leukemia virus type 1 infection leads to arrest in the G1 phase of the cell cycle. J. Virol. 2008, 82, 8442–8455. [Google Scholar] [CrossRef]
- Jones, K.S.; Petrow-Sadowski, C.; Huang, Y.K.; Bertolette, D.C.; Ruscetti, F.W. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat. Med. 2008, 14, 429–36. [Google Scholar] [CrossRef]
- El Hajj, H.; El-Sabban, M.; Hasegawa, H.; Zaatari, G.; Ablain, J.; Saab, S.T.; Janin, A.; Mahfouz, R.; Nasr, R.; Kfoury, Y.; Nicot, C.; Hermine, O.; Hall, W.; de Thé, H.; Bazarbachi, A. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J. Exp. Med. 2010, 207, 2785–2792. [Google Scholar] [CrossRef] [PubMed]
- Kinpara, S.; Hasegawa, A.; Utsunomiya, A.; Nishitsuji, H.; Furukawa, H.; Masuda, T.; Kannagi, M. Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro and in vivo by type I interferon. J. Virol. 2009, 83, 5101–5108. [Google Scholar] [CrossRef] [PubMed]
- Chlichlia, K.; Khazaie, K. HTLV-1 Tax: Linking transformation, DNA damage and apoptotic T-cell death. Chem. Biol. Interact. 2010, 188, 359–365. [Google Scholar] [CrossRef]
- Kuo, Y.L.; Giam, C.Z. Activation of the anaphase promoting complex by HTLV-1 tax leads to senescence. EMBO J. 2006, 25, 1741–1752. [Google Scholar] [CrossRef] [PubMed]
- Hanon, E.; Stinchcombe, J.C.; Saito, M.; Asquith, B.E.; Taylor, G.P.; Tanaka, Y.; Weber, J.N.; Griffiths, G.M.; Bangham, C.R. Fratricide among CD8(+) T lymphocytes naturally infected with human T cell lymphotropic virus type I. Immunity 2000, 13, 657–664. [Google Scholar] [CrossRef]
- Asquith, B.; Zhang, Y.; Mosley, A.J.; de Lara, C.M.; Wallace, D.L.; Worth, A.; Kaftantzi, L.; Meekings, K.; Griffin, G.E.; Tanaka, Y.; Tough, D.F.; Beverley, P.C.; Taylor, G.P.; Macallan, D.C.; Bangham, C.R. In vivo T lymphocyte dynamics in humans and the impact of human T-lymphotropic virus 1 infection. Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 8035–8040. [Google Scholar] [CrossRef]
- Satou, Y.; Yasunaga, J.; Zhao, T.; Yoshida, M.; Miyazato, P.; Takai, K.; Shimizu, K.; Ohshima, K.; Green, P.L.; Ohkura, N.; Yamaguchi, T.; Ono, M.; Sakaguchi, S.; Matsuoka, M. HTLV-1 bZIP Factor Induces T-Cell Lymphoma and Systemic Inflammation in vivo. PLoS Pathog. 2011, 7, e1001274. [Google Scholar] [CrossRef]
- Shimoyama, M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br. J. Haematol. 1991, 79, 428–437. [Google Scholar] [CrossRef]
- Takasaki, Y.; Iwanaga, M.; Imaizumi, Y.; Tawara, M.; Joh, T.; Kohno, T.; Yamada, Y.; Kamihira, S.; Ikeda, S.; Miyazaki, Y.; Tomonaga, M.; Tsukasaki, K. Long-term study of indolent adult T-cell leukemia-lymphoma. Blood 2010, 115, 4337–4343. [Google Scholar] [CrossRef]
- Bazarbachi, A.; Ghez, D.; Lepelletier, Y.; Nasr, R.; de Thé, H.; El-Sabban, M.E.; Hermine, O. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol. 2004, 5, 664–672. [Google Scholar] [CrossRef] [PubMed]
- Bazarbachi, A.; Hermine, O. Treatment of adult T-cell leukaemia/lymphoma: current strategy and future perspectives. Virus Res. 2001, 78, 79–92. [Google Scholar] [CrossRef]
- Yamada, Y.; Tomonaga, M.; Fukuda, H.; Hanada, S.; Utsunomiya, A.; Tara, M.; Sano, M.; Ikeda, S.; Takatsuki, K.; Kozuru, M.; Araki, K.; Kawano, F.; Niimi, M.; Tobinai, K.; Hotta, T.; Shimoyama, M. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br. J. Haematol. 2001, 113, 375–382. [Google Scholar] [CrossRef] [PubMed]
- Tsukasaki, K.; Hermine, O.; Bazarbachi, A.; Ratner, L.; Ramos, J.C.; Harrington, W., Jr.; O’Mahony, D.; Janik, J.E.; Bittencourt, A.L.; Taylor, G.P.; Yamaguchi, K.; Utsunomiya, A.; Tobinai, K.; Watanabe, T. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J. Clin. Oncol. 2009, 27, 453–459. [Google Scholar] [CrossRef] [PubMed]
- Hermine, O.; Bouscary, D.; Gessain, A.; Turlure, P.; Leblond, V.; Franck, N.; Buzyn-Veil, A.; Rio, B.; Macintyre, E.; Dreyfus, F. , Bazarbachi, A. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N. Engl. J. Med. 1995, 332, 1749–1751. [Google Scholar] [CrossRef] [PubMed]
- Gill, P.S.; Harrington, W., Jr.; Kaplan, M.H.; Ribeiro, R.C.; Bennett, J.M.; Liebman, H.A.; Bernstein-Singer, M.; Espina, B.M.; Cabral, L.; Allen, S.; et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N. Engl. J. Med. 1995, 332, 1744–1748. [Google Scholar] [CrossRef]
- Bazarbachi, A.; Hermine, O. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1996, 13, S186–S190. [Google Scholar] [CrossRef]
- White, J.D.; Wharfe, G.; Stewart, D.M.; Maher, V.E.; Eicher, D.; Herring, B.; Derby, M.; Jackson-Booth, P.G.; Marshall, M.; Lucy, D.; Jain, A.; Cranston, B.; Hanchard, B.; Lee, C.C.; Top, L.E.; Fleisher, T.A.; Nelson, D.L.; Waldmann, T.A. The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma. Leuk. Lymphoma 2001, 40, 287–294. [Google Scholar] [CrossRef]
- Matutes, E.; Taylor, G.P.; Cavenagh, J.; Pagliuca, A.; Bareford, D.; Domingo, A.; Hamblin, M.; Kelsey, S.; Mir, N.; Reilly, J.T. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br. J. Haematol. 2001, 113, 779–784. [Google Scholar] [CrossRef]
- Hermine, O.; Allard, I.; Lévy, V.; Arnulf, B.; Gessain, A.; Bazarbachi, A.; French ATL therapy group. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol. J. 2002, 3, 276–282. [Google Scholar] [CrossRef]
- Kchour, G.; Makhoul, N.J.; Mahmoudi, M.; Kooshyar, M.M.; Shirdel, A.; Rastin, M.; Rafatpanah, H.; Tarhini, M.; Zalloua, P.A.; Hermine, O.; Farid, R.; Bazarbachi, A. Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leuk. Lymphoma 2007, 48, 330–336. [Google Scholar] [CrossRef]
- Ratner, L.; Harrington, W.; Feng, X.; Grant, C.; Jacobson, S.; Noy, A.; Sparano, J.; Lee, J.; Ambinder, R.; Campbell, N.; Lairmore, M.; AIDS Malignancy Consortium. Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. PLoS ONE 2009, 4, e4420. [Google Scholar] [CrossRef] [PubMed]
- Besson, C.; Panelatti, G.; Delaunay, C.; Gonin, C.; Brebion, A.; Hermine, O.; Plumelle, Y. Treatment of adult T-cell leukemia-lymphoma by CHOP followed by therapy with antinucleosides, alpha interferon and oral etoposide. Leuk. Lymphoma 2002, 43, 2275–2279. [Google Scholar] [CrossRef] [PubMed]
- Bazarbachi, A.; Plumelle, Y.; Carlos Ramos, J.; Tortevoye, P.; Otrock, Z.; Taylor, G.; Gessain, A.; Harrington, W.; Panelatti, G.; Hermine, O. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J. Clin. Oncol. 2010, 28, 4177–4183. [Google Scholar] [CrossRef]
- Ishitsuka, K.; Katsuya, H.; Toyota, T.; Ishizu, M.; Kunami, N.; Fujita, M.; Sasaki, H.; Takamatsu, Y.; Uchiyama, M.; Fujikane, H.; Ogata, K.; Hara, S.; Tamura, K. Interferon-α and zidovudine for relapsed/refractory adult T cell leukemia/lymphoma: Case reports of Japanese patients. Int. J. Hematol. 2010, 92, 762–764. [Google Scholar] [CrossRef] [PubMed]
- Fischl, M.A.; Richman, D.D.; Grieco, M.H.; Gottlieb, M.S.; Volberding, P.A.; Laskin, O.L.; Leedom, J.M.; Groopman, J.E.; Mildvan, D.; Schooley, R.T.; et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 1987, 317, 185–191. [Google Scholar] [CrossRef] [PubMed]
- Goodbourn, S.; Didcock, L.; Randall, R.E. Interferons: Cell signalling, immune modulation, antiviral response and virus countermeasures. J. Gen. Virol. 2000, 81, 2341–2364. [Google Scholar] [CrossRef]
- Colisson, R.; Barblu, L.; Gras, C.; Raynaud, F.; Hadj-Slimane, R.; Pique, C.; Hermine, O.; Lepelletier, Y.; Herbeuval, J.P. Free HTLV-1 induces TLR7-dependent innate immune response and TRAIL relocalization in killer plasmacytoid dendritic cells. Blood 2010, 115, 2177–2185. [Google Scholar] [CrossRef]
- Isono, T.; Ogawa, K.; Seto, A. Antiviral effect of zidovudine in the experimental model of adult T cell leukemia in rabbits. Leuk. Res. 1990, 14, 841–847. [Google Scholar] [CrossRef]
- Macchi, B.; Faraoni, I.; Zhang, J.; Grelli, S.; Favalli, C.; Mastino, A.; Bonmassar, E. AZT inhibits the transmission of human T cell leukaemia/lymphoma virus type I to adult peripheral blood mononuclear cells in vitro. J. Gen. Virol. 1997, 5, 1007–1016. [Google Scholar] [CrossRef]
- Afonso, P.V.; Mekaouche, M.; Mortreux, F.; Toulza, F.; Moriceau, A.; Wattel, E.; Gessain, A.; Bangham, C.R.; Dubreuil, G.; Plumelle, Y.; Hermine, O.; Estaquier, J.; Mahieux, R. Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors. Blood 2010, 116, 3802–3808. [Google Scholar] [CrossRef] [PubMed]
- Feng, X.; Heyden, N.V.; Ratner, L. Alpha interferon inhibits human T-cell leukemia virus type 1 assembly by preventing Gag interaction with rafts. J. Virol. 2003, 77, 13389–13395. [Google Scholar] [CrossRef] [PubMed]
- Daenke, S.; Kermode, A.G.; Hall, S.E.; Taylor, G.; Weber, J.; Nightingale, S.; Bangham, C.R. High activated and memory cytotoxic T-cell responses to HTLV-1 in healthy carriers and patients with tropical spastic paraparesis. Virology 1996, 217, 139–146. [Google Scholar] [CrossRef]
- Oliere, S.; Hernandez, E.; Lezin, A.; Arguello, M.; Douville, R.; Nguyen, T.L.; Olindo, S.; Panelatti, G.; Kazanji, M.; Wilkinson, P.; Sekaly, R.P.; Cesaire, R.; Hiscott, J. HTLV-1 evades type I interferon antiviral signaling by inducing the suppressor of cytokine signaling 1 (SOCS1). PLoS Pathog. 2010, 6, e1001177. [Google Scholar] [CrossRef] [PubMed]
- Tosi, P.; Visani, G.; Ottaviani, E.; Gamberi, B.; Cenacchi, A.; Tura, S. Synergistic cytotoxicity of AZT plus alpha and gamma interferon in chronic myeloid leukemia cell line K562. Eur. J. Haematol. 1993, 51, 209–213. [Google Scholar] [CrossRef] [PubMed]
- Bazarbachi, A.; Nasr, R.; El-Sabban, M.E.; Mahé, A.; Mahieux, R.; Gessain, A.; Darwiche, N.; Dbaibo, G.; Kersual, J.; Zermati, Y.; Dianoux, L.; Chelbi-Alix, M.K.; de Thé, H.; Hermine, O. Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma. Leukemia 2000, 14, 716–721. [Google Scholar] [CrossRef] [PubMed]
- Datta, A.; Bellon, M.; Sinha-Datta, U.; Bazarbachi, A.; Lepelletier, Y.; Canioni, D.; Waldmann, T.A.; Hermine, O.; Nicot, C. Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood 2006, 108, 1021–1029. [Google Scholar] [CrossRef]
- El Hajj, H.; Hermine, O.; de Thé, H.; Bazarbachi, A. American University of Beirut, Beirut, Lebanon; Hôpital Necker-Enfants Malades, Paris, France; INSERM, Université Paris Diderot U 7212, Unité 944, Paris, France. The combination AZT/IFN is not effective in Tax-transgenic murine ATL. Unpublished work. 2010. [Google Scholar]
- Herishanu, Y.; Pérez-Galán, P.; Liu, D.; Biancotto, A.; Pittaluga, S.; Vire, B.; Gibellini, F.; Njuguna, N.; Lee, E.; Stennett, L.; Raghavachari, N.; Liu, P.; McCoy, J.P.; Raffeld, M.; Stetler-Stevenson, M.; Yuan, C.; Sherry, R.; Arthur, D.C.; Maric, I.; White, T.; Marti, G.E.; Munson, P.; Wilson, W.H.; Wiestner, A. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011, 117, 563–574. [Google Scholar] [CrossRef] [PubMed]
- Nasr, R.; Lallemand-Breitenbach, V.; Zhu, J.; Guillemin, M.C.; de Thé, H. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin. Cancer Res. 2009, 15, 6321–6326. [Google Scholar] [CrossRef]
- Nasr, R.; Guillemin, M.C.; Ferhi, O.; Soilihi, H.; Peres, L.; Berthier, C.; Rousselot, P.; Robledo-Sarmiento, M.; Lallemand-Breitenbach, V.; Gourmel, B.; Vitoux, D.; Pandolfi, P.P.; Rochette-Egly, C.; Zhu, J.; de Thé, H. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat. Med. 2008, 14, 1333–1342. [Google Scholar] [CrossRef]
- Bazarbachi, A.; El-Sabban, M.E.; Nasr, R.; Quignon, F.; Awaraji, C.; Kersual, J.; Dianoux, L.; Zermati, Y.; Haidar, J.H.; Hermine, O.; de Thé, H. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood 1999, 93, 278–283. [Google Scholar] [CrossRef] [PubMed]
- Mahieux, R.; Pise-Masison, C.; Gessain, A.; Brady, J.N.; Olivier, R.; Perret, E.; Misteli, T.; Nicot, C. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 2001, 98, 3762–3769. [Google Scholar] [CrossRef] [PubMed]
- El-Sabban, M.E.; Nasr, R.; Dbaibo, G.; Hermine, O.; Abboushi, N.; Quignon, F.; Ameisen, J.C.; Bex, F.; de Thé, H.; Bazarbachi, A. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood 2000, 96, 2849–2855. [Google Scholar] [PubMed]
- Nasr, R.; Rosenwald, A.; El-Sabban, M.E.; Arnulf, B.; Zalloua, P.; Lepelletier, Y.; Bex, F.; Hermine, O.; Staudt, L.; de Thé, H.; Bazarbachi, A. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood 2003, 101, 4576–4582. [Google Scholar] [CrossRef] [PubMed]
- Hermine, O.; Dombret, H.; Poupon, J.; Arnulf, B.; Lefrère, F.; Rousselot, P.; Damaj, G.; Delarue, R.; Fermand, J.P.; Brouet, J.C.; Degos, L.; Varet, B.; de Thé, H.; Bazarbachi, A. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol. J. 2004, 5, 130–134. [Google Scholar] [CrossRef]
- Ishitsuka, K.; Suzumiya, J.; Aoki, M.; Ogata, K.; Hara, S.; Tamura, K. Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica 2007, 92, 719–720. [Google Scholar] [CrossRef] [PubMed]
- Heraud, J.M.; Mortreux, F.; Merien, F.; Contamin, H.; Mahieux, R.; Pouliquen, J.F.; Wattel, E.; Gessain, A.; de Thé, H.; Bazarbachi, A.; Hermine, O.; Kazanji, M. The efficacy of combined therapy of arsenic trioxide and alpha interferon in human T-cell leukemia virus type-1-infected squirrel monkeys (Saimiri sciureus). Antivir. Res. 2006, 70, 132–139. [Google Scholar] [CrossRef] [PubMed]
- Kchour, G.; Tarhini, M.; Kooshyar, M.M.; El Hajj, H.; Wattel, E.; Mahmoudi, M.; Hatoum, H.; Rahimi, H.; Maleki, M.; Rafatpanah, H.; Rezaee, S.A.; Yazdi, M.T.; Shirdel, A.; de Thé, H.; Hermine, O.; Farid, R.; Bazarbachi, A. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009, 113, 6528–6532. [Google Scholar] [CrossRef]
- Nasr, R.; El-Sabban, M.E.; Karam, J.A.; Dbaibo, G.; Kfoury, Y.; Arnulf, B.; Lepelletier, Y.; Bex, F.; de Thé, H.; Hermine, O.; Bazarbachi, A. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene 2005, 24, 419–430. [Google Scholar] [CrossRef]
- Bangham, C.R. The immune response to HTLV-I. Curr. Opin. Immunol. 2000, 4, 397–402. [Google Scholar] [CrossRef]
- Akimoto, M.; Kozako, T.; Sawada, T.; Matsushita, K.; Ozaki, A.; Hamada, H.; Kawada, H.; Yoshimitsu, M.; Tokunaga, M.; Haraguchi, K.; Uozumi, K.; Arima, N.; Tei, C. Anti-HTLV-1 tax antibody and tax-specific cytotoxic T lymphocyte are associated with a reduction in HTLV-1 proviral load in asymptomatic carriers. J. Med. Virol. 2007, 79, 977–986. [Google Scholar] [CrossRef] [PubMed]
- Hanon, E.; Hall, S.; Taylor, G.P.; Saito, M.; Davis, R.; Tanaka, Y.; Usuku, K.; Osame, M.; Weber, J.N.; Bangham, C.R. Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood 2000, 95, 1386–1392. [Google Scholar] [CrossRef] [PubMed]
- Suarez, F.; Marcais, A.; Ghez, D.; Delarue, R.; Deau-Fischer, B.; Aoun, C.; Sicre de Fontbrune, F.; Ysebaert, L.; Asnafi, V.; Canioni, D.; Bazarbachi, A.; Hermine, O. Arsenic Trioxyde in the treatment of HTLV1 associated ATLL. Retrovirology 2011, 8, A59. [Google Scholar] [CrossRef]
© 2011 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Nasr, R.; Hajj, H.E.; Kfoury, Y.; Thé, H.d.; Hermine, O.; Bazarbachi, A. Controversies in Targeted Therapy of Adult T Cell Leukemia/Lymphoma: ON Target or OFF Target Effects? Viruses 2011, 3, 750-769. https://doi.org/10.3390/v3060750
Nasr R, Hajj HE, Kfoury Y, Thé Hd, Hermine O, Bazarbachi A. Controversies in Targeted Therapy of Adult T Cell Leukemia/Lymphoma: ON Target or OFF Target Effects? Viruses. 2011; 3(6):750-769. https://doi.org/10.3390/v3060750
Chicago/Turabian StyleNasr, Rihab, Hiba El Hajj, Youmna Kfoury, Hugues de Thé, Olivier Hermine, and Ali Bazarbachi. 2011. "Controversies in Targeted Therapy of Adult T Cell Leukemia/Lymphoma: ON Target or OFF Target Effects?" Viruses 3, no. 6: 750-769. https://doi.org/10.3390/v3060750